This analysis used data from @ randomized , double-blind , placebo-controlled phase III trials of perampanel as an add-on therapy in patients with epilepsy who were experiencing refractory partial seizures : studies @ ( ClinicalTrials.gov identifier NCT@ ) , @ ( NCT@ ) , and @ ( NCT@ ) .